Reported about 21 hours ago
Tilray Brands has been diversifying away from its cannabis roots and is expected to continue this trend over the next five years. Despite a significant decline in stock value since its merger with Aphria in 2020, the company now generates more revenue from international pharmaceutical distribution and its alcohol business. With U.S. cannabis legalization prospects dimming and a recent focus on alcohol acquisitions, Tilray is likely to become predominantly an alcohol company, further reducing its cannabis operations.
Source: YAHOO